keyword
MENU ▼
Read by QxMD icon Read
search

dmards RA failure biologicals

keyword
https://www.readbyqxmd.com/read/29669391/translational-biomarkers-and-ex-vivo-models-of-joint-tissues-as-a-tool-for-drug-development-in-rheumatoid-arthritis
#1
Cecilie F Kjelgaard-Petersen, Adam Platt, Martin Braddock, Martin A Jenkins, Kishwar Musa, Emma Graham, Thorbjørn Gantzel, Gillian Slynn, Michael E Weinblatt, Morten A Karsdal, Christian S Thudium, Anne-C Bay-Jensen
OBJECTIVE: Rheumatoid arthritis (RA) is a chronic, autoimmune and degenerative joint disease leading to disability, reduced life quality, and increased mortality. Although several synthetic and biological disease modifying anti-rheumatic drugs (DMARDs) are available, there is still a medical need for novel drugs controlling disease progression. As only 10% of RA drug candidates that enter phase I trials are eventually FDA registered, there is an immediate requirement for translational drug development tools to facilitate early drug development decision making...
April 18, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29623726/the-effect-of-biological-dmards-on-the-risk-of-congestive-heart-failure-in-rheumatoid-arthritis-a-systematic-review
#2
Milad Baniaamam, Walter J Paulus, Annelies B Blanken, Michael T Nurmohamed
A common cardiovascular manifestation in rheumatoid arthritis (RA) is congestive heart failure (CHF) in which inflammation is considered to play a pivotal role. Although anti-inflammatory therapy such as biological disease-modifying anti-rheumatic drugs (bDMARDs) have the potential of improving the cardiac function and reducing the risk of CHF, the published studies showed contrasting results. This review aims to systematically summarize and analyze literature regarding the effect of bDMARDs on the cardiac function and on the risk of CHF in RA...
April 6, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29546668/tofacitinib-for-treating-rheumatoid-arthritis-after-the-failure-of-disease-modifying-anti-rheumatic-drugs-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#3
REVIEW
Lesley Uttley, Iñigo Bermejo, Shijie Ren, Marrissa Martyn-St James, Ruth Wong, David L Scott, Adam Young, Matt Stevenson
As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Pfizer) of tofacitinib (TOF; Xeljanz® ) to submit evidence of the drug's clinical and cost-effectiveness in the treatment of rheumatoid arthritis (RA) after the failure of conventional disease-modifying antirheumatic drugs (cDMARDs). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG)...
March 15, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29533750/in-early-arthritis-patients-high-haq-at-baseline-and-das28-at-three-months-predict-suboptimal-outcomes-at-two-years-a-retrospective-cohort-study
#4
Antonis Fanouriakis, Ioannis Papalopoulos, Irini Gergianaki, Giorgis Spyrou, Abdulsamet Erden, Panagiota Rapsomaniki, Maria Terizaki, Nestor Avgoustidis, Argyro Repa, Nikolaos Kougkas, George Bertsias, Dimitrios T Boumpas, Prodromos I Sidiropoulos
OBJECTIVES: Early arthritis clinics (EAC) aim to improve rheumatoid arthritis (RA) outcomes by tailoring treatment targeting to remission. Our aim was to analyse disease course and relevant predictors over 2 years in early arthritis; we also assessed the applicability of the "treat-to-target approach" in a real-life EAC. METHODS: Patients with early arthritis recruited at the EAC of the University Hospital of Heraklion were followed prospectively according to a follow-up protocol for two years, without implementing a pre-specified treatment protocol, to capture real-life practices...
February 28, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29495891/tocilizumab-in-the-treatment-of-adult-rheumatoid-arthritis
#5
Raimon Sanmartí, Virginia Ruiz-Esquide, Carla Bastida, Dolor Soy
Rheumatoid arthritis (RA) is the most prevalent immune-mediated chronic rheumatic disease and is associated with joint destruction and disability. Therapeutic strategies, including biological disease-modifying antirheumatic drugs (bDMARDs) have improved the prognosis and quality of life of RA patients. Tocilizumab (TCZ) is a humanized monoclonal antibody against IL-6 receptor licensed in 2009 that has demonstrated clinical efficacy in various adult RA populations. RA management guidelines and recommendations consider TCZ as one of the bDMARDS indicated after methotrexate or other conventional synthetic DMARDs and/or TNF inhibitors failure in adult RA...
March 2, 2018: Immunotherapy
https://www.readbyqxmd.com/read/29365183/drug-immunogenicity-in-patients-with-inflammatory-arthritis-and-secondary-failure-to-tumour-necrosis-factor-inhibitor-therapies-the-reason-study
#6
Alejandro Balsa, Raimon Sanmarti, José Rosas, Victor Martin, Ana Cabez, Susana Gómez, María Montoro
Objectives: The aims were to evaluate the prevalence of anti-drug antibodies (ADA) in patients with RA or SpA experiencing secondary failure to anti-TNF therapy and to correlate ADA presence with anti-TNF concentration and clinical response. Methods: This was a cross-sectional, observational study of patients with active RA or SpA experiencing secondary failure to etanercept (ETN), infliximab (INF) or adalimumab (ADL). Concomitant non-biologic DMARDs were permitted...
April 1, 2018: Rheumatology
https://www.readbyqxmd.com/read/29148403/treatment-patterns-in-rheumatoid-arthritis-after-discontinuation-of-methotrexate-data-from-the-ontario-best-practices-research-initiative-obri
#7
Janet E Pope, Emmanouil Rampakakis, Mohammad Movahedi, Angela Cesta, Xiuying Li, Sandra Couto, John S Sampalis, Claire Bombardier
OBJECTIVES: In active rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX), guidelines support adding or switching to another conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) and/or a biologic DMARD (bDMARD). The purpose of this analysis was to describe treatment practices in routine care and to evaluate determinants of regimen selection after MTX discontinuation. METHODS: Biologic-naïve patients in the Ontario Best Practice Research Initiatives registry discontinuing MTX due to primary/secondary failure, adverse events, or patient/physician decision were included...
October 23, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28631046/adherence-of-rheumatoid-arthritis-patients-to-biologic-disease-modifying-antirheumatic-drugs-a-cross-sectional-study
#8
Natalia Mena-Vazquez, Sara Manrique-Arija, Lucía Yunquera-Romero, Inmaculada Ureña-Garnica, Marta Rojas-Gimenez, Carla Domic, Francisco Gabriel Jimenez-Nuñez, Antonio Fernandez-Nebro
The aims of this study were to evaluate adherence of rheumatoid arthritis (RA) patients to biological disease-modifying antirheumatic drugs (bDMARDs), identify potential risk factors, and analyze the discriminative ability of the Morisky-Green test (MGT) to detect bDMARD nonadherence. One hundred and seventy-eight adult RA patients treated with bDMARDs were included. Adherence was measured using the medication possession ratio (MPR) of the previous 6 months. An MPR >80% was considered good adherence. Patient demographics, clinical characteristics, and MGT scores were assessed through a standardized clinical interview at the cross-sectional date...
October 2017: Rheumatology International
https://www.readbyqxmd.com/read/28598774/what-could-we-learn-from-the-sub-analysis-of-a-single-nation-cohort-in-a-worldwide-study-lessons-from-the-results-observed-in-the-italian-cohort-of-the-go-more-trial
#9
Roberto Giacomelli, Piero Ruscitti, Stefano Bombardieri, Giovanna Cuomo, Salvatore De Vita, Mauro Galeazzi, Monica Mecchia
OBJECTIVES: GO-MORE Trial investigated the use of Golimumab (GLM) in 3280 rheumatoid arthritis (RA) patients worldwide. At present, the burden of arthritis is greater in poorer countries than in developed countries due to socioeconomic disparities, thus suggesting the usefulness of subgroup investigations. We aimed to evaluate GLM as add-on therapy for RA patients in the Italian cohort of GO-MORE trial and compared the clinical characteristics between Italian patients and the enrolled patients worldwide...
July 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28429118/-how-frequent-are-poor-prognostic-markers-in-rheumatoid-arthritis-an-estimate-based-on-three-epidemiologic-cohorts
#10
K Albrecht, A Richter, Y Meissner, D Huscher, L Baganz, K Thiele, M Schneider, A Strangfeld, A Zink
BACKGROUND: Unfavorable prognostic factors-high disease activity, early erosions, and autoantibodies-should be considered when making treatment decisions in rheumatoid arthritis (RA). There are little data on the frequency of individual poor prognostic factors among RA patients in daily care. METHODS: Disease activity (Disease Activity Score, DAS28), erosions, antibodies against citrullinated peptides or rheumatoid factor (ACPA/RF+), previous treatment failure, inflammation markers, and functional disability (FFbH < 70) were defined as prognostic factors...
June 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28412710/triple-oral-therapy-versus-antitumor-necrosis-factor-plus-methotrexate-mtx-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-mtx-a-systematic-literature-review
#11
Julia Mary, Michel De Bandt, Cédric Lukas, Jacques Morel, Bernard Combe
OBJECTIVE: For patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX), the relative effectiveness of the combination of conventional disease-modifying antirheumatic drugs (DMARD) compared with the combination of tumor necrosis factor (TNF) inhibitors and MTX, as second-line therapy, is uncertain. The aim of this study was to compare the efficacy and tolerance of triple oral DMARD therapy versus anti-TNF agents associated with MTX in patients with RA after MTX failure...
June 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28264816/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-and-biological-disease-modifying-antirheumatic-drugs-2016-update
#12
REVIEW
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, Sofia Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Chris D Buckley, Frank Buttgereit, Vivian Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan Gomez-Reino, Laure Gossec, Jacques-Eric Gottenberg, Johanna M W Hazes, Tom Huizinga, Meghna Jani, Dmitry Karateev, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain McInnes, Eduardo Mysler, Peter Nash, Karel Pavelka, Gyula Poór, Christophe Richez, Piet van Riel, Andrea Rubbert-Roth, Kenneth Saag, Jose da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib)...
June 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28151971/eq-5d-utility-response-and-drug-survival-in-rheumatoid-arthritis-patients-on-biologic-monotherapy-a-prospective-observational-study-of-patients-registered-in-the-south-swedish-ssatg-registry
#13
Tanja Schjødt Jørgensen, Carl Turesson, Meliha Kapetanovic, Martin Englund, Aleksandra Turkiewicz, Robin Christensen, Henning Bliddal, Pierre Geborek, Lars Erik Kristensen
OBJECTIVES: Biologic agents have dramatically changed treatment of rheumatoid arthritis (RA). To date only scarce head-to-head data exist especially when the biological therapies are given as monotherapy without concomitant disease modifying drugs (DMARDs). Thus the objective of the current study is to evaluate treatment response of all available biological therapies with special focus on utility (EQ-5D-3L) and drug survival of biologic DMARDs (bDMARDs) prescribed as monotherapy in RA patients in southern Sweden...
2017: PloS One
https://www.readbyqxmd.com/read/28132102/comparative-effectiveness-of-treatment-options-after-conventional-dmards-failure-in-rheumatoid-arthritis
#14
Yoon-Kyoung Sung, Soo-Kyung Cho, Dam Kim, Chan-Bum Choi, Soyoung Won, So-Young Bang, Hoon-Suk Cha, Jung-Yoon Choe, Won Tae Chung, Seung-Jae Hong, Jae-Bum Jun, Hyoun Ah Kim, Jinseok Kim, Seong-Kyu Kim, Tae-Hwan Kim, Hye-Soon Lee, Jaejoon Lee, Jisoo Lee, Shin-Seok Lee, Sung Won Lee, Yeon-Ah Lee, Seong-Su Nah, Chang-Hee Suh, Dae-Hyun Yoo, Bo Young Yoon, Sang Cheol Bae
OBJECTIVE: To compare the clinical effectiveness of two treatment strategies for active rheumatoid arthritis (RA) refractory to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs): starting TNF inhibitors (TNFIs) or changing csDMARDs. METHODS: We used two nationwide Korean RA registries for patient selection. TNFI users were selected from the BIOPSY, which is an inception cohort of RA patients starting biologic DMARDs. As a control group, we selected RA patients with moderate or high disease activity from the KORONA database whose treatment was changed to other csDMARDs...
June 2017: Rheumatology International
https://www.readbyqxmd.com/read/28079512/long-term-treatment-response-in-rheumatoid-arthritis-patients-starting-adalimumab-or-etanercept-with-or-without-concomitant-methotrexate
#15
COMPARATIVE STUDY
Merel J l'Ami, Eva L Kneepkens, Michael T Nurmohamed, Charlotte L M Krieckaert, Ingrid M Visman, Gert-Jan Wolbink
OBJECTIVES: To observe long-term clinical response and drug survival in a prospective two-year cohort study in rheumatoid arthritis (RA) patients starting adalimumab or etanercept treatment, with or without methotrexate (MTX), after failure of conventional DMARD therapy, including MTX. METHODS: Disease activity score of 28 joints (DAS28) and Health Assessment Questionnaire (HAQ) were collected of 873 consecutive RA patients, treated with adalimumab or etanercept, prospectively at baseline, 4, 16, 28, 40, 52, 78 and 104 weeks of biological therapy...
May 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27855242/biologic-or-tofacitinib-monotherapy-for-rheumatoid-arthritis-in-people-with-traditional-disease-modifying-anti-rheumatic-drug-dmard-failure-a-cochrane-systematic-review-and-network-meta-analysis-nma
#16
REVIEW
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Peter Tugwell, George A Wells
BACKGROUND: We performed a systematic review, a standard meta-analysis and network meta-analysis (NMA), which updates the 2009 Cochrane Overview, 'Biologics for rheumatoid arthritis (RA)'. This review is focused on biologic monotherapy in people with RA in whom treatment with traditional disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) had failed (MTX/other DMARD-experienced). OBJECTIVES: To assess the benefits and harms of biologic monotherapy (includes anti-tumor necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or non-TNF (abatacept, anakinra, rituximab, tocilizumab)) or tofacitinib monotherapy (oral small molecule) versus comparator (placebo or MTX/other DMARDs) in adults with RA who were MTX/other DMARD-experienced...
November 17, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27722215/jak-inhibitors-a-broadening-approach-in-rheumatoid-arthritis
#17
S Lam
Pfizer's Xeljanz (tofacitinib citrate) was the first Janus kinase (JAK) inhibitor to reach the market for rheumatoid arthritis (RA) following its U.S. approval in November 2012, and it has since gained approval in more than 45 countries as a second-line therapy for RA after failure of disease-modifying antirheumatic drugs (DMARDs). This emerging category has heralded an attractive new class of oral treatment options in RA, with a notable opportunity in patients who stop responding to DMARDs, but they are facing a challenging market...
August 2016: Drugs of Today
https://www.readbyqxmd.com/read/27721905/combination-therapy-with-biologic-agents-in-rheumatic-diseases-current-and-future-prospects
#18
REVIEW
Kentaro Inui, Tatsuya Koike
Strategies in rheumatoid arthritis (RA) based on 'treat to target' aim to control disease activity, minimize structural damage, and promote longer life. Several disease-modifying antirheumatic drugs (DMARDs) have been shown to be effective including biological DMARDs (bDMARDs). Treatment guidelines and recommendations for RA have also been published. According to those guidelines, conventional synthetic DMARDs (csDMARDs), as monotherapy or combination therapy, should be used in DMARD-naïve patients, irrespective of the addition of glucocorticoids (GCs)...
October 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27518855/-the-first-biologic-for-rheumatoid-arthritis-factors-influencing-the-therapeutic-decision
#19
D Pattloch, A Richter, B Manger, R Dockhorn, L Meier, H-P Tony, A Zink, A Strangfeld
BACKGROUND AND AIMS: Biologics (disease modifying antirheumatic drugs, bDMARD) have been in use in Germany for the treatment of rheumatoid arthritis (RA) since 2001, usually after failure of at least one conventional synthetic (cs)DMARD. We analyzed temporal changes in factors that influence the decision for either a first bDMARD or a further csDMARD. MATERIAL AND METHODS: We analyzed data from 9513 bDMARD-naive RA patients in the German biologics register RABBIT who switched to a new therapy...
April 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/27443588/cardiovascular-safety-findings-in-patients-with-rheumatoid-arthritis-treated-with-tofacitinib-an-oral-janus-kinase-inhibitor
#20
Christina Charles-Schoeman, Pierre Wicker, Miguel A Gonzalez-Gay, Mary Boy, Andrea Zuckerman, Koshika Soma, Jamie Geier, Kenneth Kwok, Richard Riese
OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The implications of treatment with tofacitinib on cardiovascular (CV) risk in RA are unknown. Therefore, CV adverse events (AEs), and blood pressure and lipid level changes, in tofacitinib-treated patients with RA were evaluated. METHODS: Data were pooled from six Phase (P)3 studies (24 months) and two open-label long-term extension (LTE) studies (60 months) of tofacitinib in patients with RA and inadequate response to DMARDs...
December 2016: Seminars in Arthritis and Rheumatism
keyword
keyword
111811
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"